Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Valcarcel, David  [Clear All Filters]
2014
Cadenas IGarcía, Valcarcel D, Martino R, Piñana JL, Barba P, Novelli S, Esquirol A, Garrido A, Saavedra S, Granell M, et al. Impact of Cyclosporine Levels on the Development of Acute Graft versus Host Disease after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation. Mediators Inflamm. 2014;2014:620682.
Törlén J, Ringdén O, Le Rademacher J, Batiwalla M, Chen J, Erkers T, Ho V, Kebriaei P, Keever-Taylor C, Kindwall-Keller T, et al. Low CD34 Dose is Associated with Poor Survival after Reduced Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2014.
2020
Nazha A, Hu Z-H, Wang T, R Lindsley C, Abdel-Azim H, Aljurf M, Bacher U, Bashey A, Cahn J-Y, Cerny J, et al. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Myelodysplastic Syndromes Patients. Biol Blood Marrow Transplant. 2020.
Zhou Z, Nath R, Cerny J, Wang H-L, Zhang M-J, Abdel-Azim H, Agrawal V, Ahmed G, A Al-Homsi S, Aljurf M, et al. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020;4(13):3180-3190.
2021
Sahebi F, Eikema D-J, Koster L, Kröger N, Meijer E, van Doesum JA, Rovira M, Koc Y, Angelucci E, Blaise D, et al. Post-Transplant Cyclophosphamide for Graft vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type: A Study from the Chronic Malignancies Working Party of the EBM. Transplant Cell Ther. 2021.
2022
Montoro MJulia, Pomares H, Coll R, Del Castillo TBernal, Tormo M, Jiménez A, Brunet S, Casaño J, Oiartzabal I, Díez-Campelo M, et al. Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice. Leuk Lymphoma. 2022:1-12.
Berastegui N, Ainciburu M, Romero JP, Garcia-Olloqui P, Alfonso-Pierola A, Philippe C, Vilas-Zornoza A, San Martin-Uriz P, Ruiz-Hernández R, Abarrategi A, et al. The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes. Nat Commun. 2022;13(1):7619.
2023
Platzbecker U, Porta MGiovanni D, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong ISoo, et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet. 2023.
Szabolcs P, Mazor RD, Yackoubov D, Levy S, Stiff P, Rezvani A, Hanna R, Wagner J, Keating A, Lindemans CA, et al. Immune Reconstitution Profiling Suggests Antiviral Protection After Transplantation with Omidubicel: a Phase 3 Substudy. Transplant Cell Ther. 2023.
Orgueira AMosquera, Encinas MMateo Pere, Varela NADiaz, Mora E, Díaz-Beyá M, Montoro MJulia, Pomares H, Ramos F, Tormo M, Jerez A, et al. Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes. Hemasphere. 2023;7(10):e961.
Lin C, Schwarzbach A, Sanz J, Montesinos P, Stiff P, Parikh S, Brunstein C, Cutler C, Lindemans CA, Hanna R, et al. Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials. Transplant Cell Ther. 2023.
Ainciburu M, Ezponda T, Berastegui N, Alfonso-Pierola A, Vilas-Zornoza A, San Martin-Uriz P, Alignani D, de Espinosa JLamo, San Julian M, Solas TJiménez, et al. Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single cell resolution. Elife. 2023;12.
2024
Torres-Esquius S, Beas F, Chen-Liang THua, Pomares H, Santiago M, Varela NDíaz, Liquori A, Hernandez F, Xicoy B, Hermosín L, et al. Germline assessment for alloHSCT candidates over 50 years: A 'Fast-Track' screening in myeloid neoplasms. Br J Haematol. 2024.